According to the World Health Organization, car-diovascular diseases caused 16.6 million
deaths worldwide (29.3% of all deaths) in 2001. Coronary heart disease was the leading …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …

Background Both aspirin and clopidogrel reduce the rate of cardiovascular events in
patients with coronary heart disease. We estimated the cost effectiveness of the increased …

Atherothrombosis describes the superimposition of a thrombus on a ruptured atherosclerotic
plaque, and is the primary cause of acute ischemic events. Atherothrombosis is a …

Background: The optimal aspirin dose for the prevention of cardiovascular events remains
controversial. Objective: To assess the incidence of and risk factors for adverse clinical …

[Aspirin for primary prevention of asymptomatic atherosclerosis]. - Abstract - Europe PMC Sign
in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …

Atherothrombosis is the most common cause of an acute ischemic event. Antiplatelet agents
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …

This is a comment on" Cost effectiveness of aspirin, clopidogrel, or both for secondary
prevention of coronary heart disease." N Engl J Med. 2002 Jun 6; 346 (23): 1800-6. This is a …

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …